Deep Immunomics Platform Technology

ImmunoScape’s Deep Immunomics platform utilizes proprietary combinatorial barcoding technologies allowing discovery of rare, therapeutically relevant T cells and their T cell receptor (TCR). Our platform allows large scale T cell mining of patient samples while retaining extraordinarily high sensitivity, regularly detecting antigen-specific CD8 T cells at frequencies as low as 0.001%.

1. PBMC or TIL samples from patients with disease of interest

  • ImmunoScape’s Deep Immunomics platform is agnostic to sample type enabling mining of T cells from peripheral blood and tumor-infiltrating lymphocytes
  • Our library of highly prevalent HLA alleles enables identification of antigen-specific T cells in ~85% of patients across North America, Europe, and Eastern Asia

2. TargetScape®

  • ImmunoScape’s proprietary target screening platform mines hundreds to thousands of samples at the millions of cells scale
  • We routinely screen samples using peptide-MHC multimers representing hundreds of candidate TCR targets
  • We identify samples with T cells of therapeutic interest and use their phenotype to guide hit selection

3. TCR Antigen Profiling (TAP)

  • We focus single cell sequencing efforts on tumor antigen-specific T cells identified and prioritized using TargetScape®
  • TCR sequence, phenotype, gene expression, and clonality data are extracted from prioritized T cells at the thousands of cells scale

4. TCR Assessment

  • We evaluate and prioritize novel tumor antigen-specific TCRs identified using TAP
  • TCRs are advanced into further development based on in vitro and in vivo models of efficacy, safety, and specificity
Top